|SP-141 is a MDM2 inhibitor. It acts by exerting excellent in-vitro and in-vivo anticancer activity.
|SJ-172550 is a small molecule inhibitor of MDMX and competes for the wild type p53 peptide binding to MDMX with an EC50 of 5 μM.
|SAR405838 is a highly potent and selective MDM2 inhibitor, binds to MDM2 with Ki= 0.88 nM and has high specificity over other proteins.
|RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays).
|RITA induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. It is MDM2-p53 interaction inhibitor and activates p53 expression.
|RG7388 is a potent and selective p53–MDM2 inhibitor which can block the binding of MDM2 to p53 with IC50 value of 30 nM.
|RG7112 is a small-molecule MDM2 antagonist which can occupy the p53-binding pocket of MDM2.
|PROTAC MDM2 Degrader-3
|PROTAC MDM2 Degrader-3 is a MDM2 degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.
|PK11195 is a 2‑Phenylindolylglyoxylyldipeptide Murine Double Minute2 (MDM2)/Translocator Protein (TSPO)/Human Constitutive Androstane Receptor (hCAR) Inhibitor, and is potentially useful for the Treatment of Gliomas.
|NVP-CGM097 stereoisomer is a stereoisomer of NVP-CGM097.
|NVP-CGM097 is a potent, selective and species specific p53-Mdm2 inhibitor with IC50 of 1.7±0.1 nM.
|Nutlin 3b is a MDM2/p53 antagonist or inhibitor with IC50 of 13.6 μM.
|Nutlin 3a is an improved MDM2-p53 interation antagonist thus acting as p53 (TP53) activator and stabilizer. It is a more potent diastereoisomer of Nutlin-3.
|Nutlin 3(Random Configuration) is an MDM2 antagonist which can activate p53 pathway through inhibition of p53-MDM2 interaction.
|Nutlin 3 is an MDM2 antagonist which can activate p53 pathway through inhibition of p53-MDM2 interaction.
|NSC 66811 is a potent MDM2 inhibitor with Ki value of 120 nM which can disrupt MDM2-p53 interaction and activate p53 function.
|NSC 59984 is a reactivator of p53 which targets various mutant p53 to restore wild-type p53 pathway via the activation of p73 in cancer cells. It could induce p53 mutant protein degradation via MDM2-mediated ubiquitination.
|MX69 is a dual inhibitor of MDM2 and XIAP which can induce MDM2 downregulation resulted not only in inhibition of XIAP expression, but also in activation of p53.
|MD-224 is a potent small-molecule MDM2 degrader which induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells.
|MA242 is a Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. MA242 decreased cell proliferation and induced apoptosis in pancreatic cancer cell lines regardless of p53 status. MA242 alone or in combination with gemcitabine inhibited pancreatic tumor growth and metastasis without any host toxicity. Our data indicate that targeting both MDM2 and NFAT1 represents a novel and effective strategy to treat pancreatic cancer.
|HDM201 binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction of the two proteins and leading to the activation of the p53 pathway. It induces robust p53-dependent cell cycle arrest and apoptosis in human p53 wild-type tumor cells. HDM201 exhibits highly selectivity across a panel of cancer cell lines.
|Milademetan tosylate hydrate
|DS-3032b is an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity.
|BI-0252 is a chemically stable and orally active inhibitors of the MDM2-p53 interaction.
|PROTAC PARP1 degrader
|at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM.
|APG-115 is a compound with a very high affinity to MDM2 (Ki < 1 nM), potent cellular activity, and an excellent oral pharmacokinetic profile.